ReviewCureus2023
Association Between Apolipoprotein B and Coronary Artery Disease Among Hypertensive Patients: A Systematic Review of the Prospective and Retrospective Studies.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Effect of Bariatric Surgery on the Apolipoprotein B/Apolipoprotein A1 Ratio and Insulin Resistance.Obesity surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The predictive value of apolipoprotein B (apo B) has been proven in the development of coronary artery disease (CAD) among normotensives only, but it has not been directly studied in hypertensive patients. The objective of this study is to explore the association between apo B and CAD among patients with hypertension. Search strategies were conducted on September 24, 2022, and involved the databases PubMed, Web of Science, and Scopus. The current systematic review included observational case-control and cohort study design involving adult humans, both hypertensives and normotensives. The selected studies were restricted to those written in the English language and published after 2000. Reviews, interventional, animal, and overlapping studies, grey literature, and articles without full text were excluded from the current study. The modified Newcastle-Ottawa Scale was used to assess the risk of bias for the screened studies after data extraction. Out of 3644 publications, only five studies were included in the review, including 5222 participants. Of those, 2335 were hypertensive, 733 of them developed CAD, and 296 normotensive subjects developed CAD. The average apo B was 1.09 g/l and 1.07 g/l for hypertensives and normotensives, respectively. The risk of developing CAD is higher in patients with hypertension, or those with higher apo B. Moreover, the risk of CAD was exacerbated in hypertensive participants with elevated apo B. This systematic review highlights the independent power of apo B on the development of CAD among both hypertensive and normotensive subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.